Today’s news / Lundbeck’s billion-dollar epilepsy drug buy
The company Lundbeck wants to buy an American biotech company for about 17 billion kroner. (Archive photo). Photo: Ida Guldbæk Arentsen/Ritzau Scanpix

Lundbeck’s billion-dollar epilepsy drug buy

Lundbeck is acquiring Longboard Pharmaceuticals for $2.5 billion to secure an epilepsy drug, Bexicaserin, targeting rare conditions like Dravet and Lennox-Gastaut syndromes. Bexicaserin has blockbuster potential with projected annual sales of $2 billion and a planned launch for the end of 2028....

Get full access to Danish News in English

Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.


Already a subscriber?